Background and purpose: Patients suffering from basilar artery occlusion (BAO) and treated with intravenous thrombolysis are, in some centers, started on adjunct anticoagulation in hyperacute settings. We aimed to assess the outcome of such patients and to compare low-molecular weight heparin (LMWH) and unfractionated heparin (UFH) in this context. Methods: We examined 211 patients with angiography-proven BAO treated with intravenous thrombolysis and either adjunct UFH or LMWH. Main outcome variables were rate of symptomatic intracranial hemorrhage (sICH) according to European Cooperative Acute Stroke Study II criteria and modified Rankin Scale (mRS) at 3 months. Results: The overall rate of sICH was 11.4% and driven by the UFH group (13.3%). None of the LMWH group developed sICH. Recanalization rate did not significantly differ between the LMWH and UFH groups. An additional propensity analysis was made to balance anticoagulation groups regarding baseline characteristics. Propensity analysis showed a significant difference in sICH rate (0.0% vs. 14.8%, P = 0.044) in favor of LMWH. Independent outcome (mRS score 0-2) was achieved in a total of 31.0% and in 44.8% and 29.1% in the LMWH and UFH group, respectively (P = 0.09). Propensity analysis showed a significant difference in the risk of ending up bedridden or dead (mRS score 5-6; 34.5% vs. 63.0%, P = 0.033) in favor of LMWH. Conclusions: Our study showed a lower rate of sICH and a shift towards improved outcome in thrombolysed patients with BAO treated with LMWH as compared with UFH.
Introduction
Basilar artery occlusion (BAO) is the most devastating form of acute ischaemic stroke with a mortality of up to 80-95% if recanalization does not occur [1] [2] [3] . With novel multimodal recanalization therapies, about onethird of patients reach independent outcome [4] [5] [6] . However, due to the lack of randomized controlled trials, treatment protocols vary greatly between stroke centers. Although primary endovascular treatment (EVT) has also become a more frequent intervention in posterior circulation occlusions, recent systematic data suggest that recanalization occurs in more than 70% of patients with BAO with fibrinolytic treatments alone [6] .
In addition to recanalization therapy, some centers apply adjunct anticoagulation (AC) to prevent reocclusion of the basilar artery [3, 7] , where reocclusion has been reported to occur at rates from 10% to 30% [8] [9] [10] . However, full AC increases the risk of symptomatic intracranial hemorrhage (sICH) and is therefore often kept as a contraindication for intravenous thrombolysis (IVT), especially in anterior circulation strokes. The rates of sICH in BAO vary greatly in different registries, i.e. between 6% and 30% [5, 11] . Furthermore, the potentially differential occurrence of post-thrombolytic sICH in anterior and posterior circulation has long been debated [5, [12] [13] [14] [15] . The inhouse protocol of our hospital [16] [17] [18] [19] , with a catchment area of 1.5 million inhabitants, has for over two decades recommended starting adjunct full therapeutic dose AC to prevent reocclusion at the time of thrombolysis in an angiographically proven BAO after ICH is ruled out by neuroimaging.
Our protocol was revised in 2013. Previously, unfractionated heparin (UFH) was used and required dose adjustments based on activated partial thromboplastin time target [7] . However, the revised protocol recommends the use of low-molecular weight heparin (LMWH) instead of UFH. Although UFH may provide rapid effective AC, LMWH has a longer plasma half-life and more stable and predictable dose response, and therefore has easier subcutaneous dosing and no need for laboratory monitoring [20] . UFH has been replaced by LMWH in the treatment of several other medical conditions, due to better outcomes and safety [21] [22] [23] . However, to our knowledge, no comparison between the safety and efficiency of UFH versus LMWH has been made in IVT-treated patients with BAO. This study reports the outcomes and, in particular, the risk of sICH in a long series of patients with BAO treated with IVT combined with either UFH or LMWH administration.
Patients and methods

Patients
All patients with BAO treated in the Department of Neurology, Helsinki University Hospital were prospectively registered into our database since 1995. Additional data were retrieved from patient charts retrospectively. No approval by the ethics committee or informed consent was required as the data were collected as a part of routine hospital care. The cohort for this study comprised 211 patients with angiographyproven BAO treated with IVT and adjunct full therapeutic dose AC with either UFH or LMWH until 2017. In UFH treatment, the activated partial thromboplastin time target was set between 75 and 100 s [7] . In the LMWH group, a 30-mg intravenous bolus of enoxaparin was followed by 1 mg/kg twice per day. Patients treated with EVT were excluded as the main interest in this study was to compare adjunct AC treatments in an otherwise homogenously treated cohort. National Institutes of Health Stroke Scale (NIHSS) score was obtained for all patients before thrombolysis treatment. Imaging was performed on admission for all patients with either computed tomography (CT) or magnetic resonance imaging accompanied by angiography (CT angiography, MR angiography or digital subtraction angiography). Control imaging was obtained in all but one patient approximately 24 h after thrombolysis and additional CT was obtained whenever clinical deterioration occurred. The extent of baseline ischaemia was evaluated with the posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS) [24] .
Outcome measures
Outcome was defined as modified Rankin Scale (mRS) score at 3 months and was assessed by a certified neurologist either by personal appointment or telephone interview. The mRS score was dichotomized as independent (mRS score 0-2) versus dependent or dead (mRS score 3-6). Secondary outcome measures were being bedridden or dead (mRS score 5-6) and being dead at 3 months. sICH was defined according to European Cooperative Acute Stroke Study II criteria [25] . sICH data were available for 210 patients (control imaging not performed for one UFH-treated patient). Recanalization was assessed by experienced neuroradiologists from control CT angiography/MR angiography images obtained approximately 24 h after IVT. Recanalization data were available for 153 of all 211 patients (72.5%) and dichotomized as partial to complete (thrombolysis in myocardial infarction score 2-3) and nil to minimal (thrombolysis in myocardial infarction score 0-1) [26] . The main reason for missing recanalization data was the lack of control angiography due to the patient's poor clinical condition.
Statistical analysis
Dichotomous variables were compared with Pearsons's chi-square test or Fisher's exact test, as appropriate. Distribution of the continuous variables was tested for normality. Univariate analyses were performed with t-test for normally distributed variables or with Mann-Whitney U-test for non-normally distributed data. Well-balanced multivariate regression models were precluded due to unfitting group sizes and scarce sICH events. Therefore, we used the propensity score to reduce the effect of confounding and to make better adjusted comparisons between balanced groups [27] . SPSS 22 (IBM, Armonk, NY, USA) was used for statistical analysis.
Results
Out of 211 patients, 182 (86.3%) were treated with UFH and 29 (13.7%) were treated with LMWH (Table 1) . Most, i.e. 97.8% of UFH-treated patients, were treated before 2014. The groups were different in that the patients in the LMWH group were older and used antiplatelet therapy more often prior to BAO. On admission, they had less extensive ischaemic lesions evaluated as pc-ASPECTS < 8 and were less likely to present with stepwise progressive symptoms. Median door-to-needle time and onset-to-treatment time for IVT were significantly shorter in the LMWH group. LMWH-treated patients tended to have milder symptoms on admission, although with overlapping NIHSS group distribution. Other demographics and admission parameters did not differ between groups ( Table 1 ).
The total rate of sICH was 11.4% (24/210) ( Table 2 ). All of these sICH occurred in UFH-treated patients (24/181, 13.3%), whereas no patients in the LMWH group developed sICH (P = 0.052). Other factors associated with sICH were previous history of stroke (P = 0.029), pc-ASPECTS < 8 (P = 0.003), lower baseline platelet count (P = 0.021), longer doorto-needle time with median of 278 vs. 131 min (P = 0.036) and higher post-thrombolysis systolic blood pressure at 2 h (P = 0.015) ( Table 2) . sICH was associated with poor outcome and death (P < 0.0001) ( Table 3) . None of the patients who developed sICH had a 3-month mRS score of 0-3 (P < 0.0001) and 91.7% were dead at 3 months (P < 0.0001) ( Table 2) .
Independent outcome was achieved in a total of 31.3% (66/211 of the whole cohort) ( Table 1 ) and 39.3% (83/211) died within 3 months. Overall, 48.3% (102/211) of patients were bedridden or dead (mRS Table 1 Demographics, admission and post-treatment characteristics and outcome per anticoagulation group score 5-6) at 3 months. Independent outcome (mRS score 0-2) was achieved in 44.8% and 29.1% in the LMWH and UFH group, respectively (P = 0.090) ( Table 1 ). In the LMWH group, 34.5% had mRS score 5-6, compared with 50.5% in the UFH group (P = 0.108). Death rates were 27.6% and 41.2% (P = 0.163) in the LMWH and UFH groups, respectively (Table 1) . Patient outcomes by adjunct AC treatment groups are shown in Fig. 1 . Factors associated with poor outcome in univariate analysis are shown in Table 3 . There was a trend towards association of LMWH treatment and independent outcome (P = 0.090). All of the patients who developed sICH had a poor outcome (mRS score 4-6, P < 0.0001) ( Table 2 ). Recanalization at 24 h (n = 153) was significantly associated with independent outcome (P < 0.0001) ( Table 3) . In propensity analysis, 29 patients with LMWH were matched with 27 UFH-treated patients with similar baseline characteristics (total of 56 patients) ( Table 4 ). Demographics between groups were well balanced (Table 4) . No patients in the LMWH group and 4 of 27 (14.8%) in the UFH group developed sICH and this difference was statistically significant (P = 0.044). Ending up bedridden or dead was significantly more common in the UFH group compared with the LMWH group (mRS score 5-6, 63.0% vs. 34.5%, P = 0.033). There was also a trend towards better outcome (mRS score 0-2, 44.8% vs. 22.2%, P = 0.074) and lower death rate (27.6% vs. 51.9%, P = 0.064) in the LMWH group compared with the UFH group.
Discussion
The rate of sICH in our cohort was 11.4%, driven entirely by the UFH-treated patients (13.3% of them), as none of the LMWH-treated patients developed sICH. An additional propensity analysis was made to balance AC groups regarding baseline characteristics and there was a significant difference in sICH rate between LMWH-and UFH-treated patients (Table 4) . These data were accompanied by compatible outcome results, indicating a clinically meaningful protocol change in BAO management. The lack of sICHs in the LMWH group supports a safer AC, whereas treatment with UFH seemed to be associated with sICH in propensity analysis. The heparin dosages and ICH rates in our cohort are in line with results from other studies [9, 28, 29] and a similar LMWH regimen is used in both myocardial infarction and venous thromboembolic events with similar results, favoring LMWH with lower risk of hemorrhagic complications [21] [22] [23] .
The sICH rate in the present study is similar to previously reported by us [7, 17, 18] and others. Huemer et al. [28] reported a similar rate of 12.5% in their small analysis of 16 patients with BAO treated with IVT and adjunct heparin. These rates are higher than the 6% in the BASICS registry [5] . This difference might be partly due to sICH data not being systematically evaluated in the BASICS registry. The rate of sICH in the present BAO cohort is also higher than the rates of 1.7%-8.8% of sICH reported in anterior circulation strokes [12, 13, 15, 25, 30, 31] .
Independent outcome was achieved in one-third of the patients and mortality was 40% at 3 months, which is in line with previous reports by us and others [3, 5, 11, [16] [17] [18] . Approximately half of patients ended up bedridden or dead. In our current analysis, independent outcome was achieved by 45% in the LMWH group compared with 29% in the UFH group, both univariate and additional propensity analysis showing this remarkable but statistically non-significant trend (Tables 1 and 4 , Fig. 1) . None of the patients who developed sICH reached independent outcome. In propensity analysis, mRS score 5-6 was significantly more common in UFH-treated compared with LMWH-treated patients ( Table 4 ). The avoidance of sICH is a key safety target in recanalization therapies to minimize the hazard of non-independent survival or death.
Full-dose AC combined with IVT is commonly considered to be contraindicated due to the increased risk of bleeding. There has, however, been discussion as to whether the rate of sICH might be slightly lower in posterior circulation strokes [5, [12] [13] [14] [15] , whereas the rate of reocclusions is also significantly high in BAO [19] . We and others have used the empirically evolved practice of full-dose AC in prevention of reocclusion after IVT in BAO since 1995 [16, 19, 29] . As no evidence-based uniform guidelines exist, it is important to publish the results of this protocol. Our in-house protocol has, for a long time, recommended the routine use of UFH and only in recent years has this been changed to LMWH. As data are accumulating to support the use of EVT in posterior circulation occlusions [6] , patients with BAO in our center are increasingly being treated with thrombectomy, but were not included in this cohort. Consequently, the AC groups are quite imbalanced in size. Groups also differed with regard to many baseline characteristics (Table 1) . Patients in the UFH group had more commonly extended ischaemic changes on admission scan and longer door-to-needle time. There was also a clinically relevant trend towards higher NIHSS score at baseline in UFH-treated patients. All of these factors have previously been reported to be associated with unfavorable outcome [17, 18, 32] . This may partly explain the differences in outcome between the groups. Patients in the LMWH group were older and had more often used previous antiplatelet therapy. These differences between the groups are mainly explained by earlier suspicion, rapid diagnostics and more strictly obeying the in-house protocol in recent years, which may be reflected in shorter delays and less frequent extensive baseline ischaemic changes in more recent, LMWH-treated patients.
We are aware of limitations in our observational study. As mentioned above, the groups were not wellbalanced according to group sizes and baseline characteristics, which might have some impact on outcome variables and their statistical analyses. Recanalization data were available for only about 70% of studied patients. Although we have a large single-center cohort of thrombolysis-treated patients with BAO, the data available for the present analysis did not support reliable multivariate regression analysis, mainly due to unequal group sizes and zero frequency of sICH events in the LMWH group.
To conclude, our study shows that the rate of postthrombolytic sICH seemed to be lower with adjunct LMWH treatment compared with UFH treatment. None of the LMWH-treated patients developed sICH. There was also a trend towards better outcome in LMWH treatment compared with UFH treatment. The risk of ending up bedridden or dead was lower with LMWH treatment. Even though the full-dose AC combined with IVT is not a widely endorsed treatment strategy, it is important to publish the results of this empirically evolved practice of preventing reocclusions in this devastating form of stroke. EVT will influence the considerations regarding the AC or antiplatelet adjuvant regimen, but safe antithrombotic medications to prevent reocclusions will continue to be a challenge in BAO. EVT is still not available as widely as IVT. Therefore, more data should be made public from large individual centers and patient registries. In the meantime, our results favor LMWH over UFH when AC is administered in BAO treated with IVT.
